IRB failings compromise trial safety and validity; OHRP

By Nick Taylor

- Last updated on GMT

Related tags Institutional review board Irb

Numerous members of IRBs have conflicts of interest, lack the necessary expertise and fail to follow HHS regulations, according to the OHRP.

The findings were published by the Office for Human Research Protections (OHRP) in a review of institutional review board (IRB) activities.

In the review, which is based on compliance oversight determination letters from the past few years, the OHRP details numerous IRB failings that could have an impact on the safety and validity of clinical trials.

One of the significant findings is that IRB members voted on protocols on which they were also investigators, which contravenes US Department of Health and Human Services (HHS) regulations.

In addition to these conflicts of interest the composition of some IRBs is flawed, with the members collectively lacking the background and experience required by the HHS.

Race, gender, cultural backgrounds and sensitivity to issues such as community attitudes, in relation to the locality of the research, must all be considered when forming an IRB.

As well as failing to comply with this some IRBs have lacked a member who is not associated with the institution the board is reviewing.

Further composition errors were made by not including a non-scientist in expedited review procedures and failing to have a prisoner or suitable representative present when reviewing trials on inmates.

These oversights may be attributed to the IRB chairperson and members lack of understanding of the HHS regulations. Deviation from these regulations is raised in the review, with particular reference to not comprehending the regulations that are in place to safeguard the rights and welfare of human subjects.

However, the OHRP also puts the difficulties facing IRBs in context, saying that the boards are under resourced. In particular they lack sufficient meeting space and staff to perform their review and recordkeeping duties.

The complete OHRP review can be found here​.

Related news

Show more

Related products

show more

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 16-Jan-2023 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Optimizing Adherence in DCTs

Optimizing Adherence in DCTs

PPD - Decentralized Clinical Trials | 12-Jan-2023 | Technical / White Paper

Prioritizing greater patient-centricity and creating an opportunity to reach unprecedented patient groups, decentralized and hybrid clinical trials are...

PPD is Supporting Complex EU DCTs

PPD is Supporting Complex EU DCTs

PPD - Decentralized Clinical Trials | 05-Jan-2023 | Technical / White Paper

PPD supports European DCTs and clinical trial sponsors with a holistic and comprehensive approach

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 14-Dec-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us


View more